Dr. Silverstein answers: 'What If More Cancer is Found During Lumpectomy?' — -- Question: What will the surgeon do if more cancer is evident during lumpectomy surgery? Answer: If more cancer is ...

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance ...

INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to identify residual cancer and ...

Many patients undergoing lumpectomy surgery at NYU Langone Medical Center for the removal of an early detected breast tumor - the surgical option of choice for this diagnosis -- are benefitting from ...

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today ...

In a clinical trial of 406 patients, Mass General Cancer Center investigators found that real-time imaging using a fluorescent agent had a favorable impact for 1 in 10 patients, with potential to ...

The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...

Many women who are diagnosed with breast cancer face the difficult decision of whether to have a lumpectomy with radiation or a mastectomy with reconstruction. With the availability of study results ...

As many as 40% of lumpectomies leave positive margins that necessitate a second surgery, but a novel fluorescent imaging agent used along with a direct visualization system may improve complete ...

NEWTON, Mass., Dec. 18, 2025 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced a new collaboration with ...